Blackmores’s Acquisition of Probiotec’s Impromy brand

Arnold Bloch Leibler has advised ASX-listed Probiotec Limited on the sale

Probiotec is a leading manufacturer, marketer and distributor of a diverse, high quality range of prescription and over-the-counter pharmaceuticals and complementary medicines. Over the past week, Probiotec has announced the sale of the Impromy brand to Blackmores, the sale of a number of pharmaceutical brands to iNova Pharmaceuticals and the sale and lease back of its manufacturing facility in Laverton North.

Impromy is a weight-management program that Probiotec co-developed with the CSIRO and is supported by strong research and clinical studies.

Blackmores – Australia’s leading natural health company – will acquire Impromy for $9 million with the sale expected to be completed by November 2018.

Arnold Bloch Leibler advised Probiotec Limited with a team including Jeremy Lanzer (Picture) and Anna Sandiford.

Involved fees earner: Jeremy Lanzer – Arnold Bloch Leibler;

Law Firms: Arnold Bloch Leibler;

Clients: Probiotec Limited;

Author: Michael Patrini